EAU Edu Platform on GU cancers
Upcoming event
Masterclass on Lasers in urology
Home
/
KEYNOTE-426 study
Back
KEYNOTE-426 study
2023-06-03
Dr. Rini elaborates on the results of the KEYNOTE-426 study: Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced ccRCC.
Share:
Previous
Next
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
I agree
Read More
